Company intelligence / Profile preview
Acurex Biosciences
San Carlos, California, United Statesacurex.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Early clinical results support the use of novel blood-based biomarkers for early detection and monitoring of Parkinson’s disease pathology. Lead therapeutic candidate CU-13001 is advancing toward IND filing with strong preclinical efficacy data in models of PD.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesBiomarkers (diagnostic tools)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Michael J. Fox Foundation for Parkinson’s ResearchStanford University, University of California, The Silverstein Foundation, National Institute on AgingParkinson’s UK – £1.59m investment through Virtual Biotech programme to advance CU‑13001 into clinical trials
Beyond the preview
Go deeper on Acurex Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acurex Biosciences.